IDEAYA Biosciences Unveils OptimUM-02 Data: Darovasertib/Crizotinib Doubles PFS in Uveal Melanoma [Yahoo! Finance]
IDEAYA Biosciences, Inc. (IDYA)
Last ideaya biosciences, inc. earnings: 3/24 06:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
months (HR 0.42, p Safety was consistent with prior experience but included hypotension and syncope likely related to PKC inhibition; investigators reported management strategies (hydration, dosing with food, holding or adjusting blood-pressure meds) and will provide detailed safety data at a conference. IDEAYA is pursuing expedited regulatory pathways using the PFS-driven accelerated approval route while OS data mature (interim OS planned mid-next year) and plans to expand development into neoadjuvant, adjuvant, and HLA-A2 positive programs. Interested in IDEAYA Biosciences, Inc.? Here are five stocks we like better. MarketBeat Week in Review – 7/15 - 7/19 IDEAYA Biosciences (NASDAQ:IDYA) shared top-line results from its randomized phase II/III OptimUM-02 study evaluating darovasertib in combination with crizotinib as a frontline treatment for HLA-A2 negative metastatic uveal melanoma. The webcast featured prepared remarks from Founder, President, and CEO Yujiro S. Hata and
Show less
Read more
Impact Snapshot
Event Time:
IDYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IDYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IDYA alerts
High impacting IDEAYA Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
IDYA
News
- IDEAYA Biosciences (IDYA) had its price target raised by The Goldman Sachs Group, Inc. from $31.00 to $35.00. They now have a "neutral" rating on the stock.MarketBeat
- IDEAYA Biosciences (IDYA) had its price target raised by Wells Fargo & Company from $44.00 to $48.00. They now have an "overweight" rating on the stock.MarketBeat
- IDEAYA Biosciences (IDYA) had its price target raised by Wedbush from $52.00 to $58.00. They now have an "outperform" rating on the stock.MarketBeat
- IDEAYA Biosciences (IDYA) had its price target raised by Guggenheim from $50.00 to $54.00. They now have a "buy" rating on the stock.MarketBeat
- IDEAYA Biosciences (IDYA) had its "outperform" rating reaffirmed by Royal Bank Of Canada.MarketBeat
IDYA
Earnings
- 2/17/26 - Beat
IDYA
Sec Filings
- 4/13/26 - Form 8-K
- 4/9/26 - Form 8-K
- 3/27/26 - Form SCHEDULE
- IDYA's page on the SEC website